1. Home
  2. NDMO vs IMNM Comparison

NDMO vs IMNM Comparison

Compare NDMO & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NDMO
  • IMNM
  • Stock Information
  • Founded
  • NDMO 2019
  • IMNM 2006
  • Country
  • NDMO United States
  • IMNM United States
  • Employees
  • NDMO N/A
  • IMNM N/A
  • Industry
  • NDMO Trusts Except Educational Religious and Charitable
  • IMNM Medicinal Chemicals and Botanical Products
  • Sector
  • NDMO Finance
  • IMNM Health Care
  • Exchange
  • NDMO Nasdaq
  • IMNM Nasdaq
  • Market Cap
  • NDMO N/A
  • IMNM 687.8M
  • IPO Year
  • NDMO N/A
  • IMNM 2020
  • Fundamental
  • Price
  • NDMO $9.83
  • IMNM $8.40
  • Analyst Decision
  • NDMO
  • IMNM Strong Buy
  • Analyst Count
  • NDMO 0
  • IMNM 6
  • Target Price
  • NDMO N/A
  • IMNM $26.00
  • AVG Volume (30 Days)
  • NDMO 218.6K
  • IMNM 1.4M
  • Earning Date
  • NDMO 01-01-0001
  • IMNM 05-13-2025
  • Dividend Yield
  • NDMO 6.75%
  • IMNM N/A
  • EPS Growth
  • NDMO N/A
  • IMNM N/A
  • EPS
  • NDMO N/A
  • IMNM N/A
  • Revenue
  • NDMO N/A
  • IMNM $9,041,000.00
  • Revenue This Year
  • NDMO N/A
  • IMNM N/A
  • Revenue Next Year
  • NDMO N/A
  • IMNM $1,259.12
  • P/E Ratio
  • NDMO N/A
  • IMNM N/A
  • Revenue Growth
  • NDMO N/A
  • IMNM N/A
  • 52 Week Low
  • NDMO $8.99
  • IMNM $5.15
  • 52 Week High
  • NDMO $11.24
  • IMNM $19.07
  • Technical
  • Relative Strength Index (RSI)
  • NDMO 48.18
  • IMNM 59.16
  • Support Level
  • NDMO $9.37
  • IMNM $6.96
  • Resistance Level
  • NDMO $9.65
  • IMNM $8.88
  • Average True Range (ATR)
  • NDMO 0.23
  • IMNM 0.66
  • MACD
  • NDMO 0.03
  • IMNM 0.31
  • Stochastic Oscillator
  • NDMO 68.56
  • IMNM 87.15

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: